Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),ng,1-2,23927,DB01251,Gliquidone
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),[ng] / [ml],10-40,23928,DB01251,Gliquidone
,9105542,maximum concentration in plasma Cmax,"The mean maximum concentration in plasma Cmax was 0.65 microgram/ml, (range: 0.12-2.14 micrograms/ml, coefficient of variation (CV): 82%).",Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105542/),[μg] / [ml],0.65,37553,DB01251,Gliquidone
,9105542,time to reach maximum plasma concentrations tmax,The median time to reach maximum plasma concentrations tmax was 2.25 h (range: 1.25-4.75 h).,Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105542/),h,2.25,37554,DB01251,Gliquidone
,9105542,AUC0-infinity,"The areas under the plasma concentration-time curve from zero time to infinity (AUC0-infinity) and the mean terminal elimination half-lives (t1/2 beta) were computed from those patients (N = 8) who exhibited at least five plasma levels above the limit of quantitation in the terminal log-linear phase using a two-compartment model: the mean AUC0-infinity was 5.1 micrograms.h/ml (range: 1.5-10.1 micrograms.h/ml, CV 56%).",Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105542/),[h·μg] / [ml],5.1,37555,DB01251,Gliquidone
,9105542,half-life t1/2 alpha,"The dominant half-life t1/2 alpha derived from therapeutically relevant plasma levels of gliquidone (> 80 ng/ml) was approximately 1.2 h (range: 0.4-3.0 h. CV: 71%) and the mean terminal half-life t1/2 beta was approximately 8 h (range: 5.7-9.4 h, CV: 17%).",Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105542/),h,1.2,37556,DB01251,Gliquidone
,9105542,terminal half-life t1/2 beta,"The dominant half-life t1/2 alpha derived from therapeutically relevant plasma levels of gliquidone (> 80 ng/ml) was approximately 1.2 h (range: 0.4-3.0 h. CV: 71%) and the mean terminal half-life t1/2 beta was approximately 8 h (range: 5.7-9.4 h, CV: 17%).",Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105542/),h,8,37557,DB01251,Gliquidone
,1243665,maximal plasma level,Following oral administration of a 30 mg tablet a maximal plasma level of approximately 600 ng/ml was attained after 2 to 3 h.,"[Pharmacokinetic behaviour of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243665/),[ng] / [ml],600,76504,DB01251,Gliquidone
,1243665,Urinary excretion,Urinary excretion amounted to about 5% only.,"[Pharmacokinetic behaviour of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far (author's transl)]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1243665/),%,5,76505,DB01251,Gliquidone
,14664337,stability constant,The phase solubility profile of gliquidone in aqueous HP-beta-CD vehicle resulted in an A(L) type curve with a stability constant of 1625 M(-1).,Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14664337/),1/[M],1625,89278,DB01251,Gliquidone
,1103897,maximum blood levels,"After oral application of 15 mg AR-DF 26, maximum blood levels of 370 ng/ml blood or 700 ng/ml plasma, respectively, were reached.",[Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1103897/),[ng] / [blood·ml],370,90102,DB01251,Gliquidone
,1103897,maximum blood levels,"After oral application of 15 mg AR-DF 26, maximum blood levels of 370 ng/ml blood or 700 ng/ml plasma, respectively, were reached.",[Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1103897/),[ng] / [ml],700,90103,DB01251,Gliquidone
,19533049,half-life,"Pharmacokinetic half-life of prednisolone is 2-3 h, indicating short pharmacodynamic effect duration.",Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19533049/),h,2-3,128507,DB01251,Gliquidone
,21173464,absolute bioavailability,The absolute bioavailability of glycyrrhizin in beagle dogs was 3.24%.,Determination of glycyrrhizin in dog plasma by liquid chromatography-mass spectrometry and its application in pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21173464/),%,3.24,191966,DB01251,Gliquidone
,29404062,flow rate,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),[ml] / [min],0.25,256216,DB01251,Gliquidone
,29404062,total run time,The flow rate was 0.25 mL/min and the total run time was 6 min.,"A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),min,6,256217,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,494.5,256218,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,394.5,256219,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,488.7,256220,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,530.7,256221,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,289.5,256222,DB01251,Gliquidone
,29404062,m/,"The multiple reaction monitoring (MRM) transitions, m/z 494.5→394.5 for imatinib, 488.7→401.5 for dasatinib, 530.7→289.5 for nilotinib and 528.5→403.4 for IS, were chosen to achieve high selectivity in the simultaneous analyses.","A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404062/),,528.5,256223,DB01251,Gliquidone
,17011248,flow rate,"The chromatographic separation was achieved on a monolithic octadecyl chemically modified silicagel column and a mobile phase containing 42% aqueous 0.1% HCOOH solution (v/v) and 58% acetonitrile, at a flow rate of 1 mL/min, in isocratic conditions.",Determination of glibenclamide in human plasma by liquid chromatography and atmospheric pressure chemical ionization/MS-MS detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17011248/),[ml] / [min],1,262507,DB01251,Gliquidone
,17011248,recovery,The mean recovery for glibenclamide was 98.1+/-2.8% over a concentration interval ranging from 1 to 500 ng/mL.,Determination of glibenclamide in human plasma by liquid chromatography and atmospheric pressure chemical ionization/MS-MS detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17011248/),%,98.1,262508,DB01251,Gliquidone
